ERBB2 and breast cancer: In addition, HER2 2+/ISH negative breast cancer had a small but significant survival advantage compared to HER2 1+ breast cancer (HER2 2+ vs. HER2 1+, HR 0.95, 95% CI (0.92–0.99), p = 0.01).